The company has developed an NGS-based discovery approach that allows it to more thoroughly explore the antibody repertoire produced by immunized animals.
Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.
The researchers are currently incorporating new technology that they say will shave an additional two to three weeks off their antibody generation workflow.
It will purchase AxioMx for $20 million followed by additional performance-based payments totaling up to $25 million to be paid over the next five years.
The deal gives Abcam exclusive access to more than 1,800 human diploid and haploid cell lines from Horizon's X-MAN collection.
Abcam was encouraged to buy Firefly BioWorks by its customers, who are more frequently complementing their protein analysis work with miRNA studies.
The all-cash deal gives Abcam access to Firefly's multiplex assay biomarker-detection platform.
Abcam, a Cambridge, UK-based provider of antibody microarrays, this week announced a series of management changes.
AB Sciex this week launched its new Academic Partnership Program, an initiative designed to support academic researchers in the 'omics fields.
Abcam paid $4.2 million in cash and issued $1.8 million in company stock for MitoSciences, which develops mitochondrial antibodies and assays.
Using DNA to sketch crime victims might not be a great idea, the NYTimes says.
Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.
Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.
In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.